Increased adenosine triphosphate production by peripheral blood CD4+ cells in patients with hematologic malignancies treated with stem cell mobilization agents

Human Immunology

Volumn 71, Issue 7, 2010, Pages 652-658

  Manga, Kiran ^a   Serban, Geo ^a   Schwartz, Joseph ^a   Slotky, Ronit ^a   Patel, Nita ^a   Fan, Jianshe ^a   Bai, Xiaolin ^a   Chari, Ajai ^a   Savage, David ^a   Suciu Foca, Nicole ^a   Colovai, Adriana I ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Adenosine triphosphate production; CD4 + T cell activation; Stem cell mobilization; Stem cell transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD SAMPLING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; MALE; MULTIPLE MYELOMA; NUCLEOTIDE METABOLISM; PHENOTYPE; PRIORITY JOURNAL; STEM CELL MOBILIZATION; T CELL DEPLETION; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION;

ADENOSINE TRIPHOSPHATE; CD4-POSITIVE T-LYMPHOCYTES; COLONY-STIMULATING FACTORS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PHYTOHEMAGGLUTININS; ROC CURVE; SEX CHARACTERISTICS; STEM CELLS;

EID: 77953917178     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.03.011     Document Type: Article

References (33)

1. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
2. Tricot G., Kern S.E., Barlogie B. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis. J Natl Cancer Inst 2009, 101:964-966. author reply 66-7.
3. Gribben J.G., Zahrieh D., Stephans K., Bartlett-Pandite L., Alyea E.P., Fisher D.C., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
4. Kumar S., Giralt S., Stadtmauer E.A., Harousseau J.L., Palumbo A., Bensinger W., et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009, 114:1729-1735.
5. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
6. Barlogie B., Kyle R.A., Anderson K.C., Greipp P.R., Lazarus H.M., Hurd D.D., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup trial S9321. J Clin Oncol 2006, 24:929-936.
7. Montgomery M., Cottler-Fox M. Mobilization and collection of autologous hematopoietic progenitor/stem cells. Clin Adv Hematol Oncol 2007, 5:127-136.
8. Giralt S., Stadtmauer E.A., Harousseau J.L., Palumbo A., Bensinger W., Comenzo R.L., et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009, 23:1904-1912.
9. Nervi B., Link D.C., DiPersio J.F. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006, 99:690-705.
10. Levesque J.P., Takamatsu Y., Nilsson S.K., Haylock D.N., Simmons P.J. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001, 98:1289-1297.
11. Levesque J.P., Hendy J., Takamatsu Y., Simmons P.J., Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003, 111:187-196.
12. + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996, 88:3223-3229.
13. Narayanasami U., Kanteti R., Morelli J., Klekar A., Al-Olama A., Keating C., et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001, 98:2059-2064.
14. Armitage S., Hargreaves R., Samson D., Brennan M., Kanfer E., Navarrete C. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant 1997, 20:587-591.
15. Padmanabhan A., Reich-Slotky R., Jhang J.S., Dael S., Crowder T., Colovai A.I., Schwartz J. Use of the haematopoietic progenitor cell parameter in optimizing timing of peripheral blood stem cell harvest. Vox Sang 2009, 97:153-159.
16. Porrata L.F., Litzow M.R., Inwards D.J., Gastineau D.A., Moore S.B., Pineda A.A., et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:291-298.
17. Roberts A.W. G-CSF: A key regulator of neutrophil production, but that's not all!. Growth Factors 2005, 23:33-41.
18. Mielcarek M., Graf L., Johnson G., Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 1998, 92:215-222.
19. Joshi S.S., Lynch J.C., Pavletic S.Z., Tarantolo S.R., Pirruccello S.J., Kessinger A., Bishop M.R. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: Association with donor characteristics. Blood 2001, 98:1963-1970.
20. Rutella S. Granulocyte colony-stimulating factor for the induction of T-cell tolerance. Transplantation 2007, 84(Suppl):S26-S30.
21. Condomines M., Quittet P., Lu Z.Y., Nadal L., Latry P., Lopez E., et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol 2006, 176:6631-6639.
22. Franzke A., Piao W., Lauber J., Gatzlaff P., Konecke C., Hansen W., et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: Implications for transplantation and autoimmune diseases. Blood 2003, 102:734-739.
23. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 2009, 182:4499-4506.
24. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010, 40:22-35.
25. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
26. Lawlor K.E., Campbell I.K., Metcalf D., O'Donnell K., van Nieuwenhuijze A., Roberts A.W., Wicks I.P. Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc Natl Acad Sci U S A 2004, 101:11398-11403.
27. Remberger M., Naseh N., Aschan J., Barkholt L., LeBlanc K., Svennberg P., Ringden O. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003, 32:217-223.
28. Kowalski R., Post D., Schneider M.C., Britz J., Thomas J., Deierhoi M., et al. Immune cell function testing: An adjunct to therapeutic drug monitoring in transplant patient management. Clin Transpl 2003, 17:77-88.
29. Kowalski R.J., Post D.R., Mannon R.B., Sebastian A., Wright H.I., Sigle G., et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006, 82:663-668.
30. Serban G., Whittaker V., Fan J., Liu Z., Manga K., Khan M., et al. Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy. Hum Immunol 2009, 70:882-890.
31. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
32. McDevitt L.M., Smith L.D., Somerville K.T., Corbett J.L., Shihab F.S. A retrospective assessment of pre-treatment variables on the response to darbepoetin alfa after renal transplantation. Am J Transplant 2005, 5:1948-1956.
33. Gesundheit B., Budowski E., Israeli M., Shapira M.Y., Resnick I.B., Bringer R., et al. Assessment of CD4 T-lymphocyte reactivity by the Cylex ImmuKnow assay in patients following allogeneic hematopoietic SCT. Bone Marrow Transplant 2010, 45:527-533.